Acarix announced the results from a 2024 American College of Cardiology (ACC) poster presentation by Suzanne Baron, MD, MSc, Director of Interventional Cardiology Research, Massachusetts General Hospital and Faculty at The Baim Institute for Clinical Research, to assess the cost-utility of the CADScor System for the evaluation of coronary artery disease (CAD) in a low-risk patient population presenting to the Emergency Department (ED) with chest pain. The key findings from the study revealed that the "CADScor-First" strategy was economically dominant, leading to substantial cost savings compared to alternative non-invasive cardiac testing methods in low-risk patients presenting to the ED with chest pain. Additionally, the incidence of missed cardiac events with the CADScor System was remarkably low, indicating that the anticipated economic benefit did not compromise clinical outcomes.

Moreover, in the studied patient population, a "CADScor- First" strategy had the potential to save up to $177.8 million per 100,000 patients evaluated.